Aldeyra Resubmits Reproxalap NDA to FDA

An update from Aldeyra Therapeutics ( (ALDX) ) is now available.

On June 17, 2025, Aldeyra Therapeutics announced the resubmission of a New Drug Application to the FDA for reproxalap, a treatment for dry eye disease. This follows a Complete Response Letter from the FDA in April 2025, which required additional clinical data. The resubmission includes successful results from a recent trial that addressed previous FDA concerns, potentially impacting the company’s market position in ophthalmology.

The most recent analyst rating on (ALDX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aldeyra Therapeutics stock, see the ALDX Stock Forecast page.

Spark’s Take on ALDX Stock

According to Spark, TipRanks’ AI Analyst, ALDX is a Underperform.

Aldeyra Therapeutics faces substantial financial and regulatory challenges, reflected in its low overall score. The lack of revenue and continuous losses are significant risks, compounded by negative technical indicators. The recent FDA response letter adds further uncertainty. However, strong cash reserves and a strategic board appointment provide some potential for recovery if product development succeeds.

To see Spark’s full report on ALDX stock, click here.

More about Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company focused on developing innovative therapies for immune-mediated and metabolic diseases. Their approach involves modulating protein systems to optimize multiple pathways while minimizing toxicity. Their product candidates include RASP modulators for systemic and retinal diseases, with late-stage candidates like reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for retinitis pigmentosa.

Average Trading Volume: 1,815,926

Technical Sentiment Signal: Sell

Current Market Cap: $180.9M

For a thorough assessment of ALDX stock, go to TipRanks’ Stock Analysis page.